Examkin

Question

Difficulty: MediumInfectious Diseases

An intensive care unit team is conducting morning rounds. The patient is a 68-year-old female who was admitted one week ago following an out-of-hospital cardiac arrest. She was successfully resuscitated and placed on mechanical ventilation. Three days ago, her condition became complicated with a new fever of 39.2°C (102.6°F), worsening hypoxemia, and purulent endotracheal secretions. A chest radiograph demonstrated a new right lower lobe consolidation. Empiric intravenous vancomycin and cefepime were initiated for a presumed ventilator-associated pneumonia.

Today, she exhibits significant clinical improvement. She is afebrile with a temperature of 37.1°C (98.8°F), blood pressure of 128/78 mm Hg, and heart rate of 82/min. Her ventilator settings have been successfully weaned. An endotracheal aspirate culture obtained at the onset of fever demonstrates heavy growth of Pseudomonas aeruginosa. Susceptibility testing shows the organism is susceptible to cefepime, piperacillin-tazobactam, and meropenem, but resistant to levofloxacin. No other organisms are isolated. A nasal swab polymerase chain reaction (PCR) screen for methicillin-resistant Staphylococcus aureus (MRSA) obtained three days ago is negative.

Based on the culture and susceptibility results, which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Discontinue vancomycin and continue intravenous cefepimeAnswer
  2. B
    Continue the current regimen of vancomycin and cefepime
  3. C
    Discontinue cefepime and initiate intravenous meropenem
  4. D
    Add intravenous tobramycin to the current regimen
  5. E
    Switch vancomycin to intravenous linezolid

Answer

Discontinue vancomycin and continue intravenous cefepime
The most appropriate next step in management is to discontinue vancomycin and maintain the patient on intravenous cefepime. The core principle of antibiotic stewardship in ventilator-associated pneumonia (VAP) is to initiate broad-spectrum empiric coverage (typically an anti-MRSA agent and an antipseudomonal beta-lactam) and then rapidly de-escalate once culture and susceptibility data become available. In this case, the endotracheal culture grew only Pseudomonas aeruginosa that is susceptible to cefepime. Furthermore, the rapid nasal MRSA PCR is negative. A negative MRSA nasal swab has an exceptionally high negative predictive value (>95%) for MRSA pneumonia. Because the patient is clinically improving and the pathogen is fully susceptible to the current beta-lactam, continuing vancomycin offers no added benefit. Discontinuing it minimizes the risk of nephrotoxicity and adheres strictly to stewardship guidelines.

Step-by-Step Solution

1
Assess the patient's clinical trajectory following the initiation of empiric therapy.
The patient is clinically improving, as evidenced by resolving fever and decreasing oxygen requirements.
Clinical stability is a crucial prerequisite for the safe de-escalation of antimicrobial therapy.
2
Interpret the microbiological culture data and susceptibility results.
The endotracheal culture isolated Pseudomonas aeruginosa that is susceptible to cefepime.
Targeted therapy must be directed at the definitively identified pathogen to ensure efficacy while minimizing broad-spectrum exposure.
3
Evaluate the indication for continued MRSA coverage based on screening and culture data.
The MRSA nasal PCR is negative, and respiratory cultures did not grow MRSA.
A negative MRSA nares screen has a highly reliable negative predictive value (>95%) for MRSA pneumonia, safely allowing the discontinuation of anti-MRSA agents like vancomycin.
4
Determine the optimal definitive antibiotic regimen based on stewardship principles.
Vancomycin should be discontinued, and cefepime should be continued as monotherapy.
De-escalating to monotherapy with a proven effective agent minimizes toxicity and reduces the risk of generating antimicrobial resistance.

Key Concept

Antimicrobial de-escalation in ventilator-associated pneumonia based on clinical stability, specific culture susceptibilities, and negative MRSA screening.
Rate this question

Topics

Infectious Diseases

More questions from this topic